Alnylam and GlaxoSmithKline Form Collaboration on RNAi Technology for Vaccine Production

-- Alnylam VaxiRNA(TM) Platform Applies RNAi to Enhance Vaccine Production for Influenza and Other Pathogens --
CAMBRIDGE, Mass., (BUSINESS WIRE) -- Alnylam Pharmaceuticals, Inc. /quotes/zigman/92224/quotes/nls/alny ALNY +2.08% , a leading RNAi therapeutics company, announced today it has formed a collaboration with GlaxoSmithKline (GSK) focused on Alnylam's VaxiRNA(TM) technology for certain GSK vaccine products, including influenza. VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK, a leading vaccine manufacturer, is the first company to form a collaboration accessing this new platform.